Myo-Inositol: The PCOS Supplement That Actually Restores Ovulation

← Back to articles

Myo-inositol is a sugar alcohol that acts as a second messenger inside cells for insulin signalling. It is one of the few non-prescription products with consistent randomised evidence for restoring ovulation in polycystic ovary syndrome (PCOS), with effect sizes broadly comparable to metformin and a much friendlier side-effect profile.

Mechanism in PCOS

Women with PCOS often show altered tissue distribution of myo-inositol and D-chiro-inositol, which contributes to insulin resistance and to higher ovarian androgen output. Supplementing myo-inositol appears to improve insulin signalling and is associated with lower LH, lower free testosterone, lower fasting insulin, and more regular cycles — usually over 8–12 weeks of use.

The Trial Evidence

The Unfer 2017 meta-analysis of inositols in PCOS (PMID 29042448; DOI 10.1530/EC-17-0243) pooled randomised trials and reported consistent improvements in ovulation, androgen levels, and HOMA-IR. The Raffone 2010 head-to-head trial in Gynecological Endocrinology (PMID 20222840; DOI 10.3109/09513590903366996) compared myo-inositol 4 g/day + folic acid 400 mcg to metformin 1,500 mg/day in PCOS women and found ovulation rates were similar between groups, with fewer GI side effects in the inositol arm. Smaller IVF trials suggest that inositol supplementation in the months before assisted reproduction can improve oocyte quality and reduce gonadotrophin requirements, although the evidence base is heterogeneous and not conclusive on live-birth rates.

Psychiatric Uses

At much higher doses (12–18 g/day), myo-inositol has shown benefit in panic disorder and OCD in small crossover trials — the Palatnik 2001 trial vs fluvoxamine (PMID 11386498; DOI 10.1097/00004714-200106000-00014) is the best-known example. These doses can cause loose stools but are otherwise well tolerated. The evidence base is far smaller than for PCOS and these uses are not first-line.

Practical Notes

The most-studied PCOS regimen is 2 g myo-inositol + 50 mg D-chiro-inositol twice daily with meals (the 40:1 MI:DCI ratio that mirrors physiologic plasma ratios). Hormonal and cycle effects begin at 4–8 weeks; fertility outcomes typically need 3–6 months. It can be combined safely with metformin. If conception is planned, pair with methylfolate or folic acid per usual prenatal guidance. Drug interactions are minimal.